Table 3.
Subgroup analysis of time interval from initial dose of oral anticoagulant to discharge in patients with primary discharge diagnosis of PE.
| Characteristic | Warfarin plus enoxaparin median LOS (days) (IQR) |
Rivaroxaban median LOS (days) (IQR) |
Interval P value |
|---|---|---|---|
| Age (years) | |||
| ≥60 (N = 51, 33)∗ | 3.9 (2.7, 4.9) | 0.9 (0.8, 2.1) | <0.001 |
| <60 (N = 31, 43)∗ | 2.9 (1.6, 4.9) | 0.8 (0.2, 1.1) | <0.001 |
| Classification | |||
| Stable (N = 61, 60)∗ | 3.0 (1.9, 4.8) | 0.9 (0.5, 1.6) | <0.001 |
| Submassive (N = 19, 14)∗ | 4.2 (3.0, 6.9) | 0.9 (0.5, 2.2) | <0.001 |
| Payer type | |||
| Private (N = 25, 54)∗ | 2.9 (1.8, 4.9) | 1.8 (1.5, 2.8) | <0.001 |
| Medicare/Medicaid (N = 40, 19)∗ | 3.9 (1.9, 5.8) | 3.7 (1.8, 4.5) | 0.001 |
∗ N = number in warfarin plus enoxaparin group and number in rivaroxaban group, respectively.
CrCl: creatinine clearance; IQR: interquartile range.
Massive PE not included due to low frequency of occurrences.